// App-Quantinova.ai

: Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial

Researchers

Presenter

  • Ruben A. Mesa

Principal Investigators

  • John Mascarenhas

  • Josef T. Prchal

  • Alessandro Rambaldi

  • Dmitriy Berenzon

  • Abdulraheem Yacoub

  • Claire N. Harrison

  • Mary Frances McMullin

  • Alessandro M. Vannucchi

  • Joanne Ewing

  • Casey L. O'Connell

  • Jean-Jacques Kiladjian

  • Adam J. Mead

  • Elliott F. Winton

  • David S. Leibowitz

  • Valerio De Stefano

  • Murat O. Arcasoy

  • Craig M. Kessler

  • Rosalind Catchatourian

  • Damiano Rondelli

  • Richard T. Silver

  • Andrea Bacigalupo

  • Arnon Nagler

  • Marina Kremyanskaya

  • Lonette Sandy

  • Mohamed E. Salama

  • Vesna Najfeld

  • Joseph Tripodi

  • Rona Singer Weinberg

  • Raajit K. Rampal

  • Ronald Hoffman

  • Amylou C. Dueck

Medical Centers

  • UT Health San Antonio Cancer Center, San Antonio, TX

  • Department of Bioinformatics, Mayo Clinic, Scottsdale, AZ

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

  • Hematology and Bone Marrow Transplant Unit, University of Milan, ASST Papa Giovanni XXIII, Bergamo, Italy

  • Comprehensive Cancer Center, Wake Forest Baptist Health, Comprehensive Cancer Center, Wake Forest Baptist Health, Winston Salem, NC

  • Kansas University Cancer Center, Kansas, KS

  • Department of Virology, Royal Free Hospital, London, United Kingdom

  • Queen's University Belfast, Belfast, United Kingdom

  • Center for Research and Innovation of Myeloproliferative Neoplasms,University of Florence,Florence,Italie

  • Heart of England NHS Foundation Trust, UHB, Birmingham, GBR

  • University of Southern California Keck School of Medicine, Los Angeles, CA

  • INSERM U976 Hopital Saint Louis, Paris, France

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • Winship Cancer Institute of Emory University School of Medicine, Atlanta, GA

  • Oncology Department, Palo Alto Medical Foundation Sutter Health, Cupertino, CA

  • Hematology Department, Fondazione Policlinico Universitario A. Gemelli, Universit Cattolica del Sacro Cuore, Rome, Italy

  • Duke University College of Medicine, Durham, NC

  • Georgetown University Medical Center, Washington, DC

  • Oncology Department, John H Stroger Jr. Hospital of Cook county Chicago, Illinois, Chicago

  • Division of Hematology/Oncology, University of Illinois at Chicago, Chicago, IL

  • Richard T. Silver Myeloproliferative Neoplasms Center, NewYork-Presbyterian Weill Cornell Medical Center, New York, NY

  • Hematology, Universit Cattolica del Sacro Cuore - Policlinico A. Gemelli, Roma, Italy

  • Hematology Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • Mayo Medical Laboratories, Rochester, MN

  • Division of Hematology/Medical Oncology, The Tisch Cancer Institute,Icahn School of Medicine at Mount Sinai,New York,United States;Myeloproliferative Neoplasm Research Consortium (MPN-RC),New York,United States

  • Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • New York Genome Center, New York, NY

  • Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; Myeloproliferative Neoplasm Research Consortium (MPN-RC), New York, NY

  • Biostatistics, Mayo Clinic Arizona, Scottsdale, AZ

Locations

  • United States

  • Italy

  • United Kingdom

  • France

  • Israel

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Essential thrombocythemia

  • Polycythemia vera

Biomarkers

  • Interferon

Drug/Treatment

  • Peginterferon alfa-2a

  • Hydroxyurea

  • Hydroxycarbamide

  • Interferon

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT01258856

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved